Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 191

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 191
---
) option and conversion rights granted in connection with warrants and convertible bonds of NLS or one of our subsidiaries or (ii) grants of rights to employees, directors or consultants or our subsidiaries or other persons providing services to NLS or a subsidiary to subscribe for new shares (conversion or option rights). At the extraordinary shareholders’ meeting, shareholders will be asked to approve the increase of the conditional share capital for employee and advisory options (3b) of the Company to the maximum amount of CHF( Proposal 5 above) and the increase of the conditional share capital for shareholders’ options (3c) of the Company to the maximum amount of CHF(this Proposal 6). We are bringing this proposal to our shareholders to approve that the conditional share capital for shareholders’ options (in accordance with article 3c paragraph 1 of the Articles) shall be equal to the maximum amount permitted by law (i.e. in the amount of one -halfof the new share capital to be calculated on the day of the NLS Meeting less the amount of the conditional share capital for employee and advisory options of the Company (article 3b paragraph 1 of the Articles). The increase of share capital for shareholders’ options is required to enable the consummation of the Merger Agreement. At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement. Additional information regarding conditional share capitals is set forth below in the section entitled “Conditional Share Capital” and in the proxy statement. Please also see “ Preliminary Proxy Statement, Subject To Completion — Notice Of Extraordinary Meeting Of Shareholders To Be Held On , [2025] — 6. Conditional Share Capital for Shareholders’ Options” of this proxy statement/prospectus. To approve Proposal6, a resolution passed by a Supermajority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 6. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 6. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 6.